These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 36324149)

  • 1. Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential.
    Wang X; Yang X; Yuan X; Wang W; Wang Y
    Exp Hematol Oncol; 2022 Nov; 11(1):85. PubMed ID: 36324149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.
    Elahi R; Heidary AH; Hadiloo K; Esmaeilzadeh A
    Stem Cell Rev Rep; 2021 Dec; 17(6):2081-2106. PubMed ID: 34472037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies.
    Marofi F; Saleh MM; Rahman HS; Suksatan W; Al-Gazally ME; Abdelbasset WK; Thangavelu L; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Pathak Y; Naimi A; Baradaran B; Nikoo M; Khiavi FM
    Stem Cell Res Ther; 2021 Jul; 12(1):374. PubMed ID: 34215336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering Natural Killer Cells for Cancer Immunotherapy.
    Rezvani K; Rouce R; Liu E; Shpall E
    Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.
    Zhang C; Hu Y; Xiao W; Tian Z
    Cell Mol Immunol; 2021 Sep; 18(9):2083-2100. PubMed ID: 34267335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing natural killer cells to develop next-generation cellular immunotherapy.
    Liu S; Nguyen K; Park D; Wong N; Wang A; Zhou Y
    Chronic Dis Transl Med; 2022 Dec; 8(4):245-255. PubMed ID: 36420177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies.
    Lu H; Zhao X; Li Z; Hu Y; Wang H
    Front Oncol; 2021; 11():720501. PubMed ID: 34422667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor engineered natural killer cells for cancer therapy.
    Zhang Y; Zhou W; Yang J; Yang J; Wang W
    Exp Hematol Oncol; 2023 Aug; 12(1):70. PubMed ID: 37563648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR-NK cells: A promising cellular immunotherapy for cancer.
    Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
    EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors.
    Esmaeilzadeh A; Hadiloo K; Jabbari M; Elahi R
    Life Sci; 2024 Jan; 337():122381. PubMed ID: 38145710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
    Mehta RS; Rezvani K
    Front Immunol; 2018; 9():283. PubMed ID: 29497427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy.
    Marofi F; Rahman HS; Thangavelu L; Dorofeev A; Bayas-Morejón F; Shirafkan N; Shomali N; Chartrand MS; Jarahian M; Vahedi G; Mohammed RN; Shahrokh S; Akbari M; Khiavi FM
    Stem Cell Res Ther; 2021 Mar; 12(1):200. PubMed ID: 33752707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
    Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.
    Ruppel KE; Fricke S; Köhl U; Schmiedel D
    Front Immunol; 2022; 13():822298. PubMed ID: 35371071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells.
    Hojjatipour T; Sharifzadeh Z; Maali A; Azad M
    Hum Cell; 2023 Nov; 36(6):1843-1864. PubMed ID: 37477869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy.
    Chaudhry K; Dowlati E; Bollard CM
    Expert Rev Clin Immunol; 2021 Jun; 17(6):643-659. PubMed ID: 33821731
    [No Abstract]   [Full Text] [Related]  

  • 18. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
    Nguyen S; Lacan C; Roos-Weil D
    Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IPSC-derived CAR-NK cells for cancer immunotherapy.
    Lin X; Sun Y; Dong X; Liu Z; Sugimura R; Xie G
    Biomed Pharmacother; 2023 Sep; 165():115123. PubMed ID: 37406511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.
    Liu D; Tian S; Zhang K; Xiong W; Lubaki NM; Chen Z; Han W
    Protein Cell; 2017 Dec; 8(12):861-877. PubMed ID: 28488245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.